Catalent, Inc.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals: Major
  • ISIN: US1488061029
USD
63.48
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Catalent, Inc. stock-summary
stock-summary
Catalent, Inc.
Pharmaceuticals: Major
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.
Company Coordinates stock-summary
Company Details
14 Schoolhouse Rd , SOMERSET NJ : 08873-1213
stock-summary
Tel: 1 732 5376200
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 133 Schemes (49.83%)

Foreign Institutions

Held by 310 Foreign Institutions (34.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. John Chiminski
Chairman of the Board, Chief Executive Officer
Mr. Jack Stahl
Lead Independent Director
Mr. Madhavan Balachandran
Independent Director
Mr. J. Martin Carroll
Independent Director
Mr. Rolf Classon
Independent Director
Ms. Rosemary Crane
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1,023 Million
(Quarterly Results - Sep 2024)
Net Profit:
-129 Million
stock-summary
Industry

Pharmaceuticals: Major

stock-summary
Market cap

USD 11,522 Million (Mid Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

9,934.82%

stock-summary
Debt Equity

1.30

stock-summary
Return on Equity

-5.80%

stock-summary
Price to Book

3.25